Skip to content

Advertisement

  • Oral Presentation
  • Open Access

Apoptotic chemotherapies

  • 1,
  • 1,
  • 1 and
  • 1
Breast Cancer Research20057 (Suppl 2) :S.25

https://doi.org/10.1186/bcr1068

  • Published:

Keywords

  • Cancer Cell
  • Growth Regulation
  • Taxol
  • Inhibitory Small Molecule
  • Tumor Shrinkage

Mutations derange growth regulations of cancer cells. They can also make the cells more subject to apoptosis. We have investigated two drugs that produce specific apoptotic chemotherapeutic mechanisms that cause tumor shrinkage in mice without deleterious side effects.

The small natural product b-lapachone is specifically apoptotic to a variety of cancer cells. It synergizes strongly with taxol. It seems to have several mechanisms of lethality depending on the tumor type and the drug concentration. One mechanism is to elevate the major S-phase transcription factor E2F-1, to an apoptotic concentration [1]. It is now in clinical trial.

Tumor cells often mutate to apoptosis resistance; for example, by inactivating the p53 protein. We have reported that Go6976, a kinase inhibitory small molecule, can decrease activation of the anti-apoptotic transcription factor NF-κB [2].

These two novel therapies thus specifically cause cancer cell apoptosis; one by increasing an apoptotic factor, and the other restoring apoptosis by decreasing an anti-apoptotic factor.

Authors’ Affiliations

(1)
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

References

  1. Li Y, Sun X, LaMont T, Pardee AB, Li C: Selective killing of cancer cells by b-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA. 2003, 100: 2674-2678. 10.1073/pnas.0538044100.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Biswas DK, Martin KJ, McAllister C, Cruz AP, Graner E, Dai S, Pardee AB: Apoptosis caused by chemotherapeutical inhibition of nuclear factor-kB activation. Cancer Res. 2003, 63: 290-295.PubMedGoogle Scholar

Copyright

© BioMed Central 2005

Advertisement